Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
Author(s) -
Takara L. Stanley,
Lindsay T. Fourman,
Lai Ping Wong,
Ruslan I. Sadreyev,
James M. Billingsley,
Meghan N. Feldpausch,
Isabel Zheng,
Chelsea S. Pan,
Autumn Boutin,
Hang Lee,
Kathleen E. Corey,
Martin Torriani,
David E. Kleiner,
Raymond T. Chung,
Colleen Hadigan,
Steven Grinspoon
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab019
Subject(s) - immune system , nonalcoholic fatty liver disease , medicine , hormone , immunology , disease , fatty liver
The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modulates critical metabolic pathways; however, little is known regarding effects of augmenting pulsatile GH secretion on immune function in humans. This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom